Walgreens March Sales Decrease 4.3 Percent

DEERFIELD, Ill., April 04, 2012 - Walgreens (NYSE: WAG) (NASDAQ: WAG) had March sales of $6.02 billion, a decrease of 4.3 percent from $6.29 billion for the same month in fiscal 2011.

Total front-end sales increased 2.5 percent compared with the same month in 2011, while comparable store front-end sales increased 1.2 percent. Customer traffic in comparable stores decreased 1.0 percent while basket size increased 2.2 percent.

“We continued to see growth in our front-end business, and with Easter falling on April 8 this year we anticipate that much of our Easter sales will be reflected in our April results,” said Walgreens Executive Vice President and CFO Wade Miquelon. “In addition, our new advertising circular strategy has helped drive profitable sales.” Walgreens launched its new weekly ad circular, with additional online savings, in mid-February.

Prescriptions filled at comparable stores decreased 11.4 percent in March. Calendar day shifts in March, which had one additional Friday and Saturday, and one fewer Tuesday and Wednesday compared with March 2011, negatively impacted prescriptions filled in comparable stores by 2.1 percentage points. Lower incidence of flu negatively impacted comparable store prescriptions filled by 0.7 percentage point. The negative impact on comparable store prescriptions filled due to no longer being part of the Express Scripts, Inc. pharmacy network was 10.7 percentage points. Prescriptions processed by Express Scripts comprised 12.6 percent of Walgreens prescriptions in March 2011.

March pharmacy sales decreased 8.4 percent, while comparable store pharmacy sales decreased 11.1 percent. Calendar day shifts negatively impacted pharmacy sales in comparable stores by 2.1 percentage points. Comparable store pharmacy sales also were negatively impacted by 2.5 percentage points due to generic drug introductions in the last 12 months, by 0.9 percentage point due to lower incidence of cough, cold and flu and by 10.6 percentage points due to no longer being part of the Express Scripts network. Pharmacy sales accounted for 63.5 percent of total sales for the month.

Sales in comparable stores decreased by 6.8 percent. The effect of calendar day shifts negatively impacted total comparable sales by 1.3 percentage points. The company will report combined comparable store sales for March and April with its April sales results.

Calendar year-to-date sales were $17.68 billion, a decrease of 1.8 percent from $17.99 billion in 2011.

Fiscal 2012 year-to-date sales for the first seven months were $42.83 billion, up 1.6 percent from $42.14 billion in fiscal 2011.

Walgreens opened eight stores during March, including one relocation.

At March 31, Walgreens operated 8,300 locations in all 50 states, the District of Columbia, Puerto Rico and Guam. That includes 7,847 drugstores, 150 more than a year ago, including 19 stores acquired over the last 12 months. The company also operates infusion and respiratory services facilities, specialty pharmacies and mail service facilities. Its Take Care Health Systems subsidiary manages more than 700 in-store convenient care clinics and worksite health and wellness centers.

 

 

March Comparable Sales and Prescriptions Filled

    

 

    
  

Reported

 

Calendar
Shift
Impact

 

Generics
Impact

 

Cough,
Cold, Flu
Impact

         
Total Comp Sales -6.8% -1.3% -1.6% -0.6%
         
Comp Front End 1.2% 

-

 - -
         
Comp Rx Sales -11.1% -2.1% -2.5% -0.9%
         
Comp Rx Scripts -11.4%* -2.1% - -0.7%

* Includes +3.2 percentage points from patients filling more 90-day prescriptions

Please note: Sales numbers and the adjustments shown in the table are preliminary, unaudited and subject to revision. Comparable stores are defined as those drugstore locations open for at least 12 consecutive months without closure for seven or more consecutive days and without a major remodel or a natural disaster in the past 12 months. Acquired operating locations and relocations are not included as comparable stores for the first 12 months after the acquisition or relocation.

Cautionary Note Regarding Forward-Looking Statements: Statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," “likely,” "outlook," “forecast, "would," "could," "should," “can,” “will,” "project," "intend," "plan," "continue," "sustain," "on track," "believe," "seek," "estimate," "anticipate," "may," “possible,” "assume," and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, changes in vendor, payer and customer relationships and terms, competition, industry consolidation and the effects thereof, changes in economic and business conditions, risks associated with new business and business retention initiatives and activities, failure to obtain new contracts or extensions of existing contracts, risks associated with acquisitions, joint ventures and divestitures, the ability to realize anticipated results from capital expenditures and cost reduction initiatives, and outcomes of legal and regulatory matters. These and other risks, assumptions and uncertainties are described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each of which is incorporated herein by reference, and in other documents that we file or furnish with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, Walgreens does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this report, whether as a result of new information, future events, changes in assumptions or otherwise.

 

Contact(s)

Walgreens
Media Contact:
Robert Elfinger, 847-315-2962
or
Investor Contacts:
Rick Hans, CFA, 847-315-2385
Lisa Meers, CFA, 847-315-2361
http://news.walgreens.com